Get the Stockscreener App
0.79
7.06%
-0.06
After Hours:
.79
Icecure Medical Ltd stock is traded at $0.79, with a volume of 346.16K.
It is down -7.06% in the last 24 hours and up +30.13% over the past month.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
See More
Previous Close:
$0.85
Open:
$0.86
24h Volume:
346.16K
Relative Volume:
0.56
Market Cap:
$43.85M
Revenue:
$2.91M
Net Income/Loss:
$-15.61M
P/E Ratio:
-2.0573
EPS:
-0.384
Net Cash Flow:
$-14.50M
1W Performance:
+1.28%
1M Performance:
+30.13%
6M Performance:
-33.61%
1Y Performance:
+3.93%
1-Day Range:
$0.7805
$0.8607
1-Week Range:
$0.72
$0.90
52-Week Range:
$0.48
$1.57
Icecure Medical Ltd Stock (ICCM) Company Profile
Icecure Medical Ltd Stock (ICCM) Latest News
IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023 - BioSpace
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - Marketscreener.com
Independent Study Results in Japan Demonstrate Zero (0%) Breast - GuruFocus.com
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 - GuruFocus.com
Globus Medical (NYSE:GMED) & IceCure Medical (NASDAQ:ICCM) Head-To-Head Contrast - Defense World
IceCure receives US patent allowance for cryoablation system - Investing.com
IceCure receives US patent allowance for cryoablation system By Investing.com - Investing.com Australia
IceCure Announces FDA Advisory Panel Meeting Date for Marketing - GuruFocus.com
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System - Marketscreener.com
Analytical Overview: Icecure Medical Ltd (ICCM)’s Ratios Tell a Financial Story - The Dwinnex
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablati - GuruFocus.com
Icecure Medical Ltd (ICCM) shows promising results - US Post News
Ratios in Focus: Analyzing Icecure Medical Ltd (ICCM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference - StreetInsider.com
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic - Yahoo Finance
IceCure reports high success rate in breast cancer trial By Investing.com - Investing.com Australia
Ex-ad industry employees launch a new digital agency 'itch' - afaqs!
IceCure reports high success rate in breast cancer trial - Investing.com India
Why Is Interactive Strength Stock Surging Today? - Benzinga
InCred's Aditya Sood Reveals Key Factors Behind Selecting Indraprastha Medical From Hospital Sector - Business Today
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96 - StreetInsider.com
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate - PR Newswire
The time has not yet come to remove your chips from the table: Icecure Medical Ltd (ICCM) - SETE News
What will the future hold for Icecure Medical Ltd (NASDAQ:ICCM) stock? - US Post News
FDA AdComm to discuss IceCure's ProSense on Nov. 7 - MSN
Study: Liquid Nitrogen-Based Cryoablation Safe for Treating Treating Tumors of the Lung, Bone and Soft Tissues - Imaging Technology News
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues - StockTitan
H.C. Wainwright maintains Buy rating on IceCure Medical stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy rating on IceCure Medical stock - Investing.com India
Icecure Medical Ltd (ICCM) deserves closer scrutiny - US Post News
IceCure seeks FDA nod for breast cancer treatment - Investing.com
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 - PR Newswire
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences - PR Newswire
Icecure Medical Ltd (ICCM) can make a big difference with a little luck - SETE News
Icecure Medical Ltd (ICCM) produces promising results - US Post News
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies - The Malaysian Reserve
IceCure expands patent portfolio with USPTO allowance - Investing.com
IceCure Medical Strengthens Patent Portfolio - TipRanks
IceCure Medical stock target cut, retains buy rating on Q2 results - Investing.com India
IceCure Medical stock target cut, retains buy rating on Q2 results By Investing.com - Investing.com South Africa
IceCure Medical Ltd (NASDAQ:ICCM) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: IceCure Medical reports growth and upcoming FDA panel - Investing.com India
Earnings call: IceCure Medical reports growth and upcoming FDA panel By Investing.com - Investing.com Australia
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates - MSN
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets - The Malaysian Reserve
IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024 - PR Newswire
Icecure Medical Ltd Stock (ICCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):